Pfizer's Exubera® was intended to provide a novel inhaled insulin delivery method for diabetes management. However, the product was withdrawn from the market due to poor commercial performance rather than safety concerns. The termination of this long-term safety study indicates a strategic pivot away from inhaled insulin therapies, suggesting limited future market potential for similar products. Competitors in the diabetes space may capitalize on this gap, focusing on alternative delivery methods or formulations. Diligence should consider the evolving landscape of diabetes management and the potential for inhaled therapies to regain interest with advancements in formulation technology.